VCYT logo

Veracyte (VCYT) Company Overview

Profile

Full Name:

Veracyte, Inc.

Sector:

Healthcare

Country:

United States

IPO:

October 30, 2013

Indexes:

Not included

Description:

Veracyte, Inc. is a leading company in the field of genomic diagnostics in the USA and abroad. The company was previously known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was registered in 2006, with headquarters located in South San Francisco, California. Veracyte, Inc. conducts a series of genomic tests for the detection of cancer and idiopathic pulmonary fibrosis in a CLIA-certified laboratory. The company uses advanced scientific methods such as whole transcriptome RNA sequencing and machine learning to develop tests and optimize analysis results.

Key Details

Price

$40.49

Annual Revenue

$361.05 M(+21.76% YoY)

Annual EPS

-$1.02(-100.00% YoY)

Beta

1.61

Events Calendar

Earnings

Next earnings date:

Feb 24, 2025

Recent quarterly earnings:

Nov 6, 2024

Recent annual earnings:

Feb 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 29, 25 Needham
Buy
Dec 5, 24 Goldman Sachs
Neutral
Nov 18, 24 Morgan Stanley
Underweight
Nov 8, 24 Scotiabank
Sector Outperform
Nov 7, 24 UBS
Buy
Nov 7, 24 Needham
Buy
Nov 7, 24 Goldman Sachs
Buy
Oct 17, 24 Leerink Partners
Outperform
Oct 16, 24 UBS
Buy
Oct 10, 24 Guggenheim
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Veracyte?
  • Does Veracyte pay dividends?
  • What sector is Veracyte in?
  • What industry is Veracyte in?
  • What country is Veracyte based in?
  • When did Veracyte go public?
  • Is Veracyte in the S&P 500?
  • Is Veracyte in the NASDAQ 100?
  • Is Veracyte in the Dow Jones?
  • When was Veracyte's last earnings report?
  • When does Veracyte report earnings?
  • Should I buy Veracyte stock now?

What is the ticker symbol for Veracyte?

The ticker symbol for Veracyte is NASDAQ:VCYT

Does Veracyte pay dividends?

No, Veracyte does not pay dividends

What sector is Veracyte in?

Veracyte is in the Healthcare sector

What industry is Veracyte in?

Veracyte is in the Diagnostics & Research industry

What country is Veracyte based in?

Veracyte is headquartered in United States

When did Veracyte go public?

Veracyte's initial public offering (IPO) was on October 30, 2013

Is Veracyte in the S&P 500?

No, Veracyte is not included in the S&P 500 index

Is Veracyte in the NASDAQ 100?

No, Veracyte is not included in the NASDAQ 100 index

Is Veracyte in the Dow Jones?

No, Veracyte is not included in the Dow Jones index

When was Veracyte's last earnings report?

Veracyte's most recent earnings report was on Nov 6, 2024

When does Veracyte report earnings?

The next expected earnings date for Veracyte is Feb 24, 2025

Should I buy Veracyte stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions